Lung Cancer Resources

home  » cancer resources  » lung cancer

Lung Cancer Treatment Research and

Sources of Information & Support

Kenneth S. Pope, Ph.D., ABPP

I've gathered together the following resources to help people with lung cancer and their loved ones to find information, support, and other resources. These resources are meant to complement and not replace any advice or information from a health care professional.

I created this site to be fully accessible for people with disabilities; please follow this link to change text size, color, or contrast; please follow this link for other accessibility functions for those with visual, mobility, and other disabilities.

There are 4 sections of resources:

1) 10 Books

2) 99 Recent research articles on lung cancer treatments

3) 33 Recent article on psychological aspects of lung cancer

4) 20 Links to web sites providing information and support for people with lung cancer, their loved ones, and clinicians

PLEASE NOTE: This web site includes 8 other pages of related sets of resources:



  1. Aboshi, M., Kaneko, M., & Narukawa, M. (2014). Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol, 140(5), 839-848. doi: 10.1007/s00432-014-1617-3
  2. Agustoni, F., Platania, M., Vitali, M., Zilembo, N., Haspinger, E., Sinno, V., et al. (2014). Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev, 40(1), 197-203. doi: 10.1016/j.ctrv.2013.05.005
  3. Ahn, M. J., Kim, S. W., Cho, B. C., Ahn, J. S., Lee, D. H., Sun, J. M., et al. (2014). Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. Oncologist, 19(7), 702-703. doi: 10.1634/theoncologist.2013-0419
  4. Akerley, W., Boucher, K., Rich, N., Egbert, L., Harker, G., Bylund, J., et al. (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-311. doi: 10.1016/j.lungcan.2012.12.005
  5. Al-Farsi, A., & Ellis, P. M. (2014). Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol, 4, 157. doi: 10.3389/fonc.2014.00157
  6. Asai, N., Ohkuni, Y., Kaneko, N., Yamaguchi, E., & Kubo, A. (2014). Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol, 6(2), 69-82. doi: 10.1177/1758834013517413
  7. Baisi, A., De Simone, M., Raveglia, F., & Cioffi, U. (2013). Thermal ablation in the treatment of lung cancer: present and future. Eur J Cardiothorac Surg, 43(4), 683-686. doi: 10.1093/ejcts/ezs558
  8. Bar-Sela, G., Wollner, M., Hammer, L., Agbarya, A., Dudnik, E., & Haim, N. (2013). Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 49(5), 1058-1064. doi: 10.1016/j.ejca.2012.11.007
  9. Berry, M. F., Worni, M., Pietrobon, R., D'Amico, T. A., & Akushevich, I. (2013). Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. J Thorac Oncol, 8(6), 744-752. doi: 10.1097/JTO.0b013e31828916aa
  10. Bos, M., Gardizi, M., Schildhaus, H. U., Heukamp, L. C., Geist, T., Kaminsky, B., et al. (2013). Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer, 81(1), 142-143. doi: 10.1016/j.lungcan.2013.02.018
  11. Brahmer, J. R. (2013). Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol, 31(8), 1021-1028. doi: 10.1200/JCO.2012.45.8703
  12. Broggini, M., Garassino, M. C., & Damia, G. (2013). Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Manag Res, 5, 15-20. doi: 10.2147/CMAR.S29995
  13. Brzezniak, C., Carter, C. A., & Giaccone, G. (2013). Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother, 14(2), 247-253. doi: 10.1517/14656566.2013.758714
  14. Cai, H., Lin, Y., Li, W., & Li, X. (2013). Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer, 14(4), 333-341. doi: 10.1016/j.cllc.2012.10.010
  15. Campian, J. L., Ye, X., Brock, M., & Grossman, S. A. (2013). Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest, 31(3), 183-188. doi: 10.3109/07357907.2013.767342
  16. Camps, C., Felip, E., Garcia-Campelo, R., Trigo, J. M., & Garrido, P. (2013). SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol. doi: 10.1007/s12094-013-1085-2
  17. Casal Rubio, J., Firvida-Perez, J. L., Lazaro-Quintela, M., Baron-Duarte, F. J., Alonso-Jaudenes, G., Santome, L., et al. (2014). A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer Chemother Pharmacol, 73(3), 451-457. doi: 10.1007/s00280-013-2370-z
  18. Crabtree, T., Puri, V., Timmerman, R., Fernando, H., Bradley, J., Decker, P. A., et al. (2013). Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg, 145(3), 692-699. doi: 10.1016/j.jtcvs.2012.10.038
  19. D'Arcangelo, M., & Cappuzzo, F. (2013). Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther, 13(5), 523-533. doi: 10.1586/era.13.23
  20. D'Incecco, A., & Cappuzzo, F. (2011). Gefitinib for non-small-cell lung cancer treatment. Expert opinion on drug safety.
  21. Davis, R., Fenton, P., Bayne, M., Cherrett, L., & Laurence, V. (2013). Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response. Clin Oncol (R Coll Radiol), 25(6), 389-390. doi: 10.1016/j.clon.2013.02.002
  22. Dittrich, C., Papai-Szekely, Z., Vinolas, N., Sederholm, C., Hartmann, J. T., Behringer, D., et al. (2014). A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer, 50(9), 1571-1580. doi: 10.1016/j.ejca.2014.03.007
  23. Dong, L., Han, Z. F., Feng, Z. H., & Jia, Z. Y. (2014). Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors. J Int Med Res, 42(1), 191-197. doi: 10.1177/0300060513505808
  24. Eberhardt, W. E., Mitchell, P., Schiller, J. H., Brown, M. P., Thomas, M., Mills, G., et al. (2014). Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Invest New Drugs, 32(1), 123-134. doi: 10.1007/s10637-013-9958-3
  25. Evans, W. K. (2013). Prognostic implications of treatment delays in the surgical resection of lung cancer. Thorac Surg Clin, 23(2), 225-232. doi: 10.1016/j.thorsurg.2013.01.006
  26. Felip, E., Martinez-Marti, A., Martinez, P., Cedres, S., & Navarro, A. (2013). Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol, 25(2), 115-120. doi: 10.1097/CCO.0b013e32835ca1b0
  27. Fiala, O., Pesek, M., Finek, J., Krejci, J., Bortlicek, Z., Benesova, L., et al. (2013). Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy. Neoplasma, 60(2), 129-134.
  28. Fruh, M., De Ruysscher, D., Popat, S., Crino, L., Peters, S., Felip, E., et al. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. doi: 10.1093/annonc/mdt178
  29. Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., et al. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. doi: 10.1016/S0140-6736(14)60845-X
  30. Gasic, D., Ohlhues, L., Brodin, N. P., Fog, L. S., Pommer, T., Bangsgaard, J. P., et al. (2014). A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncol, 1-7. doi: 10.3109/0284186X.2014.925578
  31. Genova, C., Rijavec, E., Truini, A., Coco, S., Sini, C., Barletta, G., et al. (2013). Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother, 14(11), 1545-1558. doi: 10.1517/14656566.2013.802774
  32. Gentzler, R. D., & Patel, J. D. (2014). Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol, 6(1), 4-15. doi: 10.1177/1758834013510589
  33. Georgoulias, V., Douillard, J. Y., Khayat, D., Manegold, C., Rosell, R., Rossi, A., et al. (2013). A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer, 14(4), 461-465. doi: 10.1016/j.cllc.2013.02.001
  34. Giuliani, J., Piacentini, P., Greco, F., Mercanti, A., Trolese, A. R., Furini, L., et al. (2014). Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly. J Chemother, 26(2), 111-116. doi: 10.1179/1973947813Y.0000000112
  35. Gridelli, C. (2013). Maintenance therapy: a new treatment paradigm in advanced nonsmall-cell lung cancer. Curr Opin Oncol, 25(2), 105-106. doi: 10.1097/CCO.0b013e32835ca1c3
  36. Gridelli, C., de Marinis, F., Ardizzoni, A., Novello, S., Fontanini, G., Cappuzzo, F., et al. (2014). Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol. doi: 10.1007/s00432-014-1715-2
  37. Gridelli, C., de Marinis, F., Cappuzzo, F., Di Maio, M., Hirsch, F. R., Mok, T., et al. (2014). Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer, 15(3), 173-181. doi: 10.1016/j.cllc.2013.12.002
  38. Groen, H. J., Socinski, M. A., Grossi, F., Juhasz, E., Gridelli, C., Baas, P., et al. (2013). A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. doi: 10.1093/annonc/mdt212
  39. Guerra, L., Meregalli, S., Zorz, A., Niespolo, R., De Ponti, E., Elisei, F., et al. (2014). Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. Eur J Nucl Med Mol Imaging, 41(4), 702-710. doi: 10.1007/s00259-013-2594-5
  40. Gwak, H. S., Joo, J., Kim, S., Yoo, H., Shin, S. H., Han, J. Y., et al. (2013). Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol, 8(5), 599-605. doi: 10.1097/JTO.0b013e318287c943
  41. Hall, R. D., Gray, J. E., & Chiappori, A. A. (2013). Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control, 20(1), 22-31.
  42. Hamaji, M., Allen, M. S., Cassivi, S. D., Deschamps, C., Nichols, F. C., Wigle, D. A., et al. (2013). Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg, 145(3), 683-690; discussion 690-681. doi: 10.1016/j.jtcvs.2012.12.051
  43. Hanna, W. C., Paul, N. S., Darling, G. E., Moshonov, H., Allison, F., Waddell, T. K., et al. (2014). Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer. J Thorac Cardiovasc Surg, 147(1), 30-33. doi: 10.1016/j.jtcvs.2013.08.060
  44. Henke, C. C., Cabri, J., Fricke, L., Pankow, W., Kandilakis, G., Feyer, P. C., et al. (2014). Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer, 22(1), 95-101. doi: 10.1007/s00520-013-1925-1
  45. Hou, Z. B., Lu, K. J., Wu, X. L., Chen, C., Huang, X. E., & Yin, H. T. (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment. Asian Pac J Cancer Prev, 15(4), 1767-1769.
  46. Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013). Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e278S-313S. doi: 10.1378/chest.12-2359
  47. Hua, X., Ward, K. C., Gillespie, T. W., Lipscomb, J., & Goodman, M. (2014). Non-small Cell Lung Cancer Treatment Receipt and Survival Among African-Americans and Whites in a Rural Area. J Community Health, 39(4), 696-705. doi: 10.1007/s10900-013-9813-7
  48. Huber, R. M., Reck, M., & Thomas, M. (2013). Current status and future strategies for multimodality treatment of unresectable stage III non-small-cell lung cancer. Eur Respir J. doi: 10.1183/09031936.00143112
  49. Jakobsen, J. N., Santoni-Rugiu, E., & Sorensen, J. B. (2014). Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. J Cancer Res Clin Oncol, 140(4), 645-652. doi: 10.1007/s00432-014-1614-6
  50. Jett, J. R., Schild, S. E., Kesler, K. A., & Kalemkerian, G. P. (2013). Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e400S-419S. doi: 10.1378/chest.12-2363
  51. Ji, K., Zhao, L. J., Liu, W. S., Liu, Z. Y., Yuan, Z. Y., Pang, Q. S., et al. (2014). Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol, 87(1035), 20130562. doi: 10.1259/bjr.20130562
  52. Jiang, X. D., Ding, M. H., Qiao, Y., Liu, Y., & Liu, L. (2014). Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases. Clin Lung Cancer, 15(2), e23-29. doi: 10.1016/j.cllc.2013.11.012
  53. Jiang, X., Ding, M., Qiao, Y., Liu, Y., & Liu, L. (2014). Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer. Clin Transl Oncol, 16(7), 630-636. doi: 10.1007/s12094-013-1129-7
  54. Kato, Y., Hotta, K., Takigawa, N., Nogami, N., Kozuki, T., Sato, A., et al. (2014). Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol, 73(5), 943-950. doi: 10.1007/s00280-014-2425-9
  55. Kim, H. R., Lee, J. C., Kim, Y. C., Kim, K. S., Oh, I. J., Lee, S. Y., et al. (2014). Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Lung Cancer, 83(2), 252-258. doi: 10.1016/j.lungcan.2013.11.008
  56. Korkmaz, T., Seber, S., Kefeli, U., Sari, E., Canhoroz, M., Oven, B., et al. (2013). Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis. Clin Transl Oncol, 15(7), 535-540. doi: 10.1007/s12094-012-0960-6
  57. Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013). Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e369S-399S. doi: 10.1378/chest.12-2362
  58. Kuiper, J. L., Heideman, D. A., Thunnissen, E., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2014). High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. Eur J Cancer, 50(7), 1399-1401. doi: 10.1016/j.ejca.2014.02.005
  59. Kumar, D. S., Noronha, V., Joshi, A., Jain, H., & Prabhash, K. (2014). Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment. Indian J Med Paediatr Oncol, 35(1), 75-78. doi: 10.4103/0971-5851.133726
  60. Laine, A. M., Westover, K. D., & Choy, H. (2014). Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. Semin Oncol, 41(1), 57-68. doi: 10.1053/j.seminoncol.2013.12.012
  61. Li, M., Tang, Z., Lin, J., Zhang, Y., Lv, S., Song, W., et al. (2014). Synergistic Antitumor Effects of Doxorubicin-Loaded Carboxymethyl Cellulose Nanoparticle in Combination with Endostar for Effective Treatment of Non-Small-Cell Lung Cancer. Adv Healthc Mater. doi: 10.1002/adhm.201400108
  62. Li, W., Zhou, F., & Zhou, C. (2014). Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther, 7, 253-261. doi: 10.2147/OTT.S45096
  63. Li, X., Wang, H., Lin, W., & Xu, Q. (2014). Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials. Curr Med Res Opin. doi: 10.1185/03007995.2014.909392
  64. Lim, S. H., Lee, J. Y., Sun, J. M., Ahn, J. S., Park, K., & Ahn, M. J. (2014). Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. J Thorac Oncol, 9(4), 506-511. doi: 10.1097/JTO.0000000000000095
  65. Liu, W. S., Zhao, L. J., Wang, S., Gong, L. L., Liu, Z. Y., Yuan, Z. Y., et al. (2014). Benefits of postoperative radiotherapy in multimodality treatment of resected small-cell lung cancer with lymph node metastasis. Eur J Surg Oncol. doi: 10.1016/j.ejso.2014.02.232
  66. Lv, S., Tang, Z., Li, M., Lin, J., Song, W., Liu, H., et al. (2014). Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials, 35(23), 6118-6129. doi: 10.1016/j.biomaterials.2014.04.034
  67. Marulli, G., Verderi, E., Zuin, A., Schiavon, M., Battistella, L., Perissinotto, E., et al. (2014). Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resectiondagger. Interact Cardiovasc Thorac Surg. doi: 10.1093/icvts/ivu141
  68. McCloskey, P., Balduyck, B., Van Schil, P. E., Faivre-Finn, C., & O'Brien, M. (2013). Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer, 49(7), 1555-1564. doi: 10.1016/j.ejca.2012.12.023
  69. Nair, V. J., MacRae, R., Sirisegaram, A., & Pantarotto, J. R. (2014). Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys, 88(2), 312-318. doi: 10.1016/j.ijrobp.2013.10.029
  70. Nieder, C., Tollali, T., Dalhaug, A., Haukland, E., Aandahl, G., Pawinski, A., et al. (2014). Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Res, 34(2), 1015-1020.
  71. Oliveira, P. I., Pereira, C. A., Belasco, A. G., & Bettencourt, A. R. (2013). Comparison of the quality of life among persons with lung cancer, before and after the chemotherapy treatment. Rev Lat Am Enfermagem, 21(3), 787-794. doi: 10.1590/S0104-11692013000300019
  72. Oshiro, Y., & Sakurai, H. (2013). The use of proton-beam therapy in the treatment of non-small-cell lung cancer. Expert Rev Med Devices, 10(2), 239-245. doi: 10.1586/erd.12.81
  73. Parsons, H. M., Harlan, L. C., Stevens, J. L., & Ullmann, C. D. (2014). Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J, 20(2), 97-104. doi: 10.1097/PPO.0000000000000039
  74. Paz-Ares, L., & Corral, J. (2014). Treatment for early-stage lung cancer: what next? Lancet, 383(9928), 1528-1530. doi: 10.1016/S0140-6736(14)60002-7
  75. Pillai, R. N., & Ramalingam, S. S. (2014). Advances in the diagnosis and treatment of non-small cell lung cancer. Mol Cancer Ther, 13(3), 557-564. doi: 10.1158/1535-7163.MCT-13-0669
  76. Powell, H. A., Tata, L. J., Baldwin, D. R., Potter, V. A., Stanley, R. A., Khakwani, A., et al. (2014). Treatment decisions and survival for people with small-cell lung cancer. Br J Cancer, 110(4), 908-915. doi: 10.1038/bjc.2013.812
  77. Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., et al. (2014). PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol, 9(2), 205-213. doi: 10.1097/JTO.0000000000000076
  78. Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., et al. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer, 15(3), 202-206. doi: 10.1016/j.cllc.2013.12.009
  79. Rossi, A., Martelli, O., & Di Maio, M. (2013). Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev, 39(5), 498-506. doi: 10.1016/j.ctrv.2012.09.006
  80. Russell, K., Healy, B., Pantarotto, J., Laurie, S. A., MacRae, R., Sabri, E., et al. (2014). Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer. Clin Lung Cancer, 15(3), 237-243. doi: 10.1016/j.cllc.2013.12.007
  81. Satouchi, M., Kotani, Y., Shibata, T., Ando, M., Nakagawa, K., Yamamoto, N., et al. (2014). Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol, 32(12), 1262-1268. doi: 10.1200/JCO.2013.53.5153
  82. Schlijper, R. C., Grutters, J. P., Houben, R., Dingemans, A. M., Wildberger, J. E., Van Raemdonck, D., et al. (2014). What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? Cancer Treat Rev, 40(1), 60-67. doi: 10.1016/j.ctrv.2013.05.004
  83. Scorsetti, M., Navarria, P., De Rose, F., Ascolese, A., Clerici, E., Franzese, C., et al. (2014). Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. J Cancer Res Clin Oncol. doi: 10.1007/s00432-014-1739-7
  84. Shah, S. U., Mashayekhi, A., Shields, C. L., Walia, H. S., Hubbard, G. B., 3rd, Zhang, J., et al. (2014). Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology, 121(1), 352-357. doi: 10.1016/j.ophtha.2013.07.014
  85. Shen, G., Bian, G., Yu, H., Gao, M., Kang, D., Shen, G., et al. (2014). Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol, 2(1), 146-150. doi: 10.3892/mco.2013.210
  86. Spathis, A., Fife, K., Blackhall, F., Dutton, S., Bahadori, R., Wharton, R., et al. (2014). Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol, 32(18), 1882-1888. doi: 10.1200/JCO.2013.54.4346
  87. Steuer, C. E., & Ramalingam, S. S. (2014). ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options. Cancer. doi: 10.1002/cncr.28597
  88. Sun, C. T., Xu, X., Sheng, W., Wang, X. W., Wen, S. L., & Han, J. Q. (2014). A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer. Bratisl Lek Listy, 115(4), 233-237.
  89. Suzuki, H., Hirashima, T., Okamoto, N., Yamadori, T., Tamiya, M., Morishita, N., et al. (2014). Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12199
  90. Tanaka, S., Aoki, M., Ishikawa, H., & Otake, Y. (2014). Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease? Gen Thorac Cardiovasc Surg, 62(6), 370-375. doi: 10.1007/s11748-014-0380-3
  91. Tang, C., Gao, H., Li, X., Liu, Y., Li, J., Qin, H., et al. (2014). Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. J Cancer Res Clin Oncol, 140(3), 427-433. doi: 10.1007/s00432-014-1582-x
  92. Tarasevych, S., Lauwers, P., Vandaele, F., & van Meerbeeck, J. P. (2014). Novel treatment options in stage I non-small-cell lung cancer. Expert Rev Anticancer Ther, 1-14. doi: 10.1586/14737140.2014.929500
  93. Tartarone, A., Lerose, R., Lazzari, C., Gregorc, V., & Aieta, M. (2014). Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Med Oncol, 31(8), 78. doi: 10.1007/s12032-014-0078-5
  94. The evolution of lung cancer treatment. (2013). Lancet, 382(9889), 286. doi: 10.1016/S0140-6736(13)61619-0
  95. Tsai, A. C., Wang, C. Y., Liou, J. P., Pai, H. C., Hsiao, C. J., Chang, J. Y., et al. (2014). Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death Dis, 5, e1162. doi: 10.1038/cddis.2014.128
  96. Wang, Q., Jiang, Z., Qi, X., Lu, S., Wang, S., Leng, C., et al. (2014). Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer. Clin Transl Oncol. doi: 10.1007/s12094-014-1190-x
  97. Wao, H., Mhaskar, R., Kumar, A., Miladinovic, B., & Djulbegovic, B. (2013). Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev, 2, 10. doi: 10.1186/2046-4053-2-10
  98. Zhu, H., Zhou, Z., Xue, Q., Zhang, X., He, J., & Wang, L. (2013). Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute. Eur J Cancer Care (Engl). doi: 10.1111/ecc.12082
  99. Zuin, A., Andriolo, L. G., Marulli, G., Schiavon, M., Nicotra, S., Calabrese, F., et al. (2013). Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer? Eur J Cardiothorac Surg, 44(2), e120-125.


PLEASE NOTE: The articles below focus specifically on lung cancer. Another page of this site addresses psychological aspects of all types of cancer: Psychological Interventions for People with Cancer: Therapy & Self-Help.

  1. Akechi, T., Okamura, H., Okuyama, T., Furukawa, T. A., Nishiwaki, Y., & Uchitomi, Y. (2009). Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. Psycho-Oncology, 18(1), 23-29.
  2. Akin, S., Can, G., Aydiner, A., Ozdilli, K., & Durna, Z. (2010). Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. European Journal of Oncology Nursing, 14(5), 400-409.
  3. Andrykowski, M. A., Steffens, R. F., Bush, H. M., & Tucker, T. C. (2013). Reports of 'growth' in survivors of non-small cell lung cancer and healthy controls: What is the value-added by the cancer experience? Psycho-Oncology, 22(10), 2214-2219.
  4. Berendes, D., Keefe, F. J., Somers, T. J., Kothadia, S. M., Porter, L. S., & Cheavens, J. S. (2010). Hope in the context of lung cancer: Relationships of hope to symptoms and psychological distress. Journal of Pain and Symptom Management, 40(2), 174-182.
  5. Bresnahan, M. J., Silk, K., & Zhuang, J. (2013). You did this to yourself! Stigma and blame in lung cancer. Journal of Applied Social Psychology, 43(Suppl 1), E132-E140.
  6. Chan, C. W. H., Richardson, A., & Richardson, J. (2011). Managing symptoms in patients with advanced lung cancer during radiotherapy: Results of a psychoeducational randomized controlled trial. Journal of Pain and Symptom Management, 41(2), 347-357.
  7. Dorman, S., Hayes, J., & Pease, N. (2009). What do patients with brain metastases from non-small cell lung cancer want from their treatment? Palliative Medicine, 23(7), 594-600.
  8. Ellis, J., Lloyd Williams, M., Wagland, R., Bailey, C., & Molassiotis, A. (2013). Coping with and factors impacting upon the experience of lung cancer in patients and primary carers. European Journal of Cancer Care, 22(1), 97-106.
  9. Floyd, A., Dedert, E., Ghate, S., Salmon, P., Weissbecker, I., Studts, J. L., et al. (2011). Depression may mediate the relationship between sense of coherence and quality of life in lung cancer patients. Journal of Health Psychology, 16(2), 249-257.
  10. Girgis, A., Lambert, S. D., McElduff, P., Bonevski, B., Lecathelinais, C., Boyes, A., & Stacey, F. (2013). Some things change, some things stay the same: A longitudinal analysis of cancer caregivers' unmet supportive care needs. Psycho-Oncology, 22(7), 1557-1564.
  11. Gonzalez, B. D., & Jacobsen, P. B. (2012). Depression in lung cancer patients: The role of perceived stigma. Psycho-Oncology, 21(3), 239-246.
  12. Hirsch, J. K., Floyd, A. R., & Duberstein, P. R. (2012). Perceived health in lung cancer patients: The role of positive and negative affect. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation, 21(2), 187-194.
  13. Kim, Y., Ryn, M., Jensen, R. E., Griffin, J. M., Potosky, A., & Rowland, J. (2014). Effects of gender and depressive symptoms on quality of life among colorectal and lung cancer patients and their family caregivers. Psycho-Oncology.
  14. Kramer, B. J., Kavanaugh, M., Trentham-Dietz, A., Walsh, M., & Yonker, J. A. (2010). Predictors of family conflict at the end of life: The experience of spouses and adult children of persons with lung cancer. The Gerontologist, 50(2), 215-225.
  15. Kramer, B. J., Kavanaugh, M., Trentham-Dietz, A., Walsh, M., & Yonker, J. A. (2010). Complicated grief symptoms in caregivers of persons with lung cancer: The role of family conflict, intrapsychic strains, and hospice utilization. Omega: Journal of Death and Dying, 62(3), 201-220.
  16. Kurita, K., Garon, E. B., Stanton, A. L., & Meyerowitz, B. E. (2013). Uncertainty and psychological adjustment in patients with lung cancer. Psycho-Oncology, 22(6), 1396-1401.
  17. Lebel, S., Castonguay, M., Mackness, G., Irish, J., Bezjak, A., & Devins, G. M. (2013). The psychosocial impact of stigma in people with head and neck or lung cancer. Psycho-Oncology, 22(1), 140-152.
  18. Lee, L. J.-H., Chung, C.-W., Chang, Y.-Y., Lee, Y.-C., Yang, C.-H., Liou, S.-H., et al. (2011). Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation, 20(3), 415-423.
  19. Lehto, R. H. (2011). Identifying primary concerns in patients newly diagnosed with lung cancer. Oncology Nursing Forum, 38(4), 440-447.
  20. Lehto, R., & Therrien, B. (2010). Death concerns among individuals newly diagnosed with lung cancer. Death Studies, 34(10), 931-946.
  21. Leppert, W., Turska, A., Majkowicz, M., Dziegielewska, S., Pankiewicz, P., & Mess, E. (2012). Quality of life in patients with advanced lung cancer treated at home and at a palliative care unit. American Journal of Hospice & Palliative Medicine, 29(5), 379-387
  22. Lindau, S. T., Surawska, H., Paice, J., & Baron, S. R. (2011). Communication about sexuality and intimacy in couples affected by lung cancer and their clinical-care providers. Psycho-Oncology, 20(2), 179-185.
  23. Margetic, B. A., Kukulj, S., Santic, Z., Jaksic, N., & Jakovljevic, M. (2013). Predicting depression with temperament and character in lung cancer patients. European Journal of Cancer Care, 22(6), 807-814.
  24. Maguire, R., Papadopoulou, C., Kotronoulas, G., Simpson, M. F., McPhelim, J., & Irvine, L. (2013). A systematic review of supportive care needs of people living with lung cancer. European Journal of Oncology Nursing, 17(4), 449-464.
  25. Milbury, K., Badr, H., & Carmack, C. L. (2012). The role of blame in the psychosocial adjustment of couples coping with lung cancer. Annals of Behavioral Medicine, 44(3), 331-340.
  26. Milette, K., El-Baalbaki, G., & Thombs, B. D. (2010). Intimacy processes and psychological distress among couples coping with head and neck or lung cancer. Psycho-Oncology, 19(11), 1235-1236.
  27. Mulcare, H., Schofield, P., Kashima, Y., Milgrom, J., Wirth, A., Bishop, M., et al. (2011). Adjustment to cancer and the information needs of people with lung cancer. Psycho-Oncology, 20(5), 488-496.
  28. Porter, L. S., Keefe, F. J., Garst, J., Baucom, D. H., McBride, C. M., McKee, D. C., et al. (2011). Caregiver-assisted coping skills training for lung cancer: Results of a randomized clinical trial. Journal of Pain and Symptom Management, 41(1), 1-13.
  29. Sanders, S. L., Bantum, E. O., Owen, J. E., Thornton, A. A., & Stanton, A. L. (2010). Supportive care needs in patients with lung cancer. Psycho-Oncology, 19(5), 480-489.
  30. Schofield, P., Ugalde, A., Gough, K., Reece, J., Krishnasamy, M., Carey, M., & Aranda, S. (2013). A tailored, supportive care intervention using systematic assessment designed for people with inoperable lung cancer: A randomised controlled trial. Psycho-Oncology, 22(11), 2445-2453.
  31. Thornton, A. A., Owen, J. E., Kernstine, K., Koczywas, M., Grannis, F., Cristea, M., & Stanton, A. L. (2012). Predictors of finding benefit after lung cancer diagnosis. Psycho-Oncology, 21(4), 365-373.
  32. Ukawa, S., Tamakoshi, A., Wakai, K., Noda, H., Ando, M., & Iso, H. (2013). Prospective cohort study on television viewing time and incidence of lung cancer: Findings from the Japan Collaborative Cohort Study. Cancer Causes & Control, 24(8), 1547-1553
  33. Yang, P., Cheville, A. L., Wampfler, J. A., Garces, Y. I., Jatoi, A., Clark, M. M., et al. (2012). Quality of life and symptom burden among long-term lung cancer survivors. Journal of Thoracic Oncology, 7(1), 64-70.


American Cancer Society: Lung Cancer: Non-small Cell

American Cancer Society: Lung Cancer: Small Cell

Canadian Cancer Society: Lung Cancer

Cancer Trials (Coalition of Cancer Cooperative Groups): Lung Cancer

Dana Farber Cancer Insitute Lung Cancer: Non-small Cell

Dana Farber Cancer Insitute Lung Cancer: Small Cell

Duke Universit: Lung Cancer

Johns Hopkins: Lung Cancer

Lung Cancer Canada

Mayo Clinical: Lung Cancer

MD Anderson Cancer Center: Lung Cancer

Memorial Sloan-Kettering Cancer Center: Lung Cancer

National Cancer Institute: Lung Cancer

Smilow Cancer Hospital at Yale-New Haven: Thoracic Oncology: Lung Cancer Treatments

Stanford Medical School Cancer Institute: Lung Cancer & Thoracic Malignancies

Toronto General Hospital: Lung Cancer

UCLA Jonnson Comprehensive Cancer Center: Lung Cancer

University of California, Davis, Cancer Center: Lung Cancer

University of Chicago Medical Center: Lung Cancer

University of Virginia Health System: Lung Cancer


[Back to Top]